Biotech

All Articles

Actinogen's cortisol blocker fails phase 2 depression research

.Actinogen Medical's cortisol blocker has actually missed out on the primary endpoint of a period 2 ...

Bivictrix chooses going personal only way to take ADC right into clinic

.Antibody-drug conjugates (ADCs) have gone to the facility of lots of a billion-dollar biobuck licen...

TPG tops up funds to $580M for assets all over lifestyle scientific researches

.Resource manager TPG, which has actually supported biotechs such as Sionna Therapeutics as well as ...

Merck stops phase 3 TIGIT trial in lung cancer cells for impossibility

.Merck &amp Co.'s TIGIT system has actually suffered another trouble. Months after shuttering a phas...

After a difficult year, Exscientia folds into Recursion

.After a year determined by pipe cuts, the departure of its own chief executive officer and unemploy...

Cullinan, after $25M bargain, return bispecific to Harbour

.Cullinan Therapy was impressed good enough with Port BioMed's bispecific invulnerable activator tha...

A more detailed examine Fierce Biotech's Brutal 15

.Within this week's incident of "The Leading Pipe," our experts are actually diving in to Fierce Bio...

Lilly deals with phase 2 breakdown of tau-targeting med

.The confetti is still flying coming from Eli Lilly's celebration celebrating the commendation of Al...

Biogen CMO Maha Radhakrishnan joins Sofinnova-- Chutes &amp Ladders

.Accept to today's Chutes &amp Ladders, our summary of significant management hirings, firings and r...

Lykos will certainly inquire FDA to reassess its selection observing being rejected of MDMA treatment for post-traumatic stress disorder

.Complying with a bad revealing for Lykos Therapies' MDMA applicant for post-traumatic stress disord...